Literature DB >> 16130190

Pharmacokinetics of mycophenolic acid in Chinese kidney transplant patients.

Xiao-Yang Lu1, Hong-Feng Huang, Jian-Zhong Sheng-Tu, Jian Liu.   

Abstract

To assess the influence of cyclosporin A (CsA) and tacrolimus (FK506) on mycophenolic acid (MPA) and correlation analysis of the pharmacokinetic parameters and patient characteristics, clinical outcome in Chinese kidney transplant recipients, the pharmacokinetics of 1000 mg mycophenolate mofetil (MMF) twice daily was measured by high-performance liquid chromatography (HPLC). PKS (Pharmaceutical Kinetics Software) 1.0.2 software package was used for the calculation of pharmacokinetic parameters. The mean C(max), t(max), and AUC((0-12))were (21.88+/-10.52) microg/ml, (1.20+/-0.95) h, and (52.546+/-13.215) microg.h/ml, respectively. The level of AUC((0-12)) in the FK506 group was significantly higher than that in the CsA group. MPA appeared not to be affected by renal function. MPA AUC((0-12)) showed statistically significant difference according to the patient's gender.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16130190      PMCID: PMC1389906          DOI: 10.1631/jzus.2005.B0885

Source DB:  PubMed          Journal:  J Zhejiang Univ Sci B        ISSN: 1673-1581            Impact factor:   3.066


  22 in total

Review 1.  Monitoring of mycophenolic acid in clinical transplantation.

Authors:  Leslie M Shaw; Thomas Pawinski; Magdalena Korecka; Arthur Nawrocki
Journal:  Ther Drug Monit       Date:  2002-02       Impact factor: 3.681

Review 2.  Therapeutic monitoring of mycophenolic acid. A consensus panel report.

Authors:  L M Shaw; A Nicholls; M Hale; V W Armstrong; M Oellerich; R Yatscoff; R E Morris; D W Holt; R Venkataramanan; J Haley; P Halloran; R Ettenger; P Keown; R G Morris
Journal:  Clin Biochem       Date:  1998-07       Impact factor: 3.281

3.  Pharmacokinetics of mycophenolate mofetil are influenced by concomitant immunosuppression.

Authors:  G Filler; M Zimmering; I Mai
Journal:  Pediatr Nephrol       Date:  2000-02       Impact factor: 3.714

Review 4.  Pharmacokinetics of mycophenolate mofetil (RS61443): a short review.

Authors:  R E Bullingham; A Nicholls; M Hale
Journal:  Transplant Proc       Date:  1996-04       Impact factor: 1.066

5.  The kinetics of mycophenolic acid and its glucuronide metabolite in adult kidney transplant recipients.

Authors:  A G Johnson; R J Rigby; P J Taylor; C E Jones; J Allen; K Franzen; M C Falk; D Nicol
Journal:  Clin Pharmacol Ther       Date:  1999-11       Impact factor: 6.875

6.  Effect of cyclosporine on mycophenolic acid trough levels in kidney transplant recipients.

Authors:  P J Gregoor; R G de Sévaux; R J Hené; C J Hesse; L B Hilbrands; P Vos; T van Gelder; A J Hoitsma; W Weimar
Journal:  Transplantation       Date:  1999-11-27       Impact factor: 4.939

7.  Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation.

Authors:  K Zucker; A Tsaroucha; L Olson; V Esquenazi; A Tzakis; J Miller
Journal:  Ther Drug Monit       Date:  1999-02       Impact factor: 3.681

8.  Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings.

Authors:  K Zucker; A Rosen; A Tsaroucha; L de Faria; D Roth; G Ciancio; V Esquenazi; G Burke; A Tzakis; J Miller
Journal:  Transpl Immunol       Date:  1997-09       Impact factor: 1.708

9.  A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.

Authors: 
Journal:  Transplantation       Date:  1996-04-15       Impact factor: 4.939

Review 10.  Clinical pharmacokinetics of mycophenolate mofetil.

Authors:  R E Bullingham; A J Nicholls; B R Kamm
Journal:  Clin Pharmacokinet       Date:  1998-06       Impact factor: 6.447

View more
  5 in total

Review 1.  Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients.

Authors:  Christine E Staatz; Susan E Tett
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

2.  Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in Chinese adult renal transplant recipients.

Authors:  Zi-Cheng Yu; Pei-Jun Zhou; Xiang-Hui Wang; Bressolle Françoise; Da Xu; Wei-Xia Zhang; Bing Chen
Journal:  Acta Pharmacol Sin       Date:  2017-08-24       Impact factor: 6.150

3.  Total and free mycophenolic acid and its 7-O-glucuronide metabolite in Chinese adult renal transplant patients: pharmacokinetics and application of limited sampling strategies.

Authors:  Zheng Jiao; Jian-Yong Zhong; Ming Zhang; Xiao-Jin Shi; Yun-Qiu Yu; Wei-Yue Lu
Journal:  Eur J Clin Pharmacol       Date:  2006-11-09       Impact factor: 2.953

4.  Population pharmacokinetic modelling for enterohepatic circulation of mycophenolic acid in healthy Chinese and the influence of polymorphisms in UGT1A9.

Authors:  Zheng Jiao; Jun-Jie Ding; Jie Shen; Hui-Qi Liang; Long-Jin Zhong; Yi Wang; Ming-Kang Zhong; Wei-Yue Lu
Journal:  Br J Clin Pharmacol       Date:  2008-02-15       Impact factor: 4.335

5.  Effect of Protein Binding on Exposure of Unbound and Total Mycophenolic Acid: A Population Pharmacokinetic Analysis in Chinese Adult Kidney Transplant Recipients.

Authors:  Changcheng Sheng; Qun Zhao; Wanjie Niu; Xiaoyan Qiu; Ming Zhang; Zheng Jiao
Journal:  Front Pharmacol       Date:  2020-03-20       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.